Catalog No.
Product Name
Application
Product Information
Citations
-
NLRP3 Inhibitor
NLRP3-IN-26 is a specific inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 0.13 μM. This compound is useful for studying the role of NLRP3 in inflammatory processes and can be applied in models of DSS-induced colitis to elucidate its impact on intestinal inflammation and immune responses. -
NLRP3 Inhibitor
NLRP3-IN-71 is a selective inhibitor of the NLRP3 inflammasome, demonstrating the ability to inhibit IL-1β secretion. This compound is characterized by its blood-brain barrier permeability and oral bioavailability, making it a valuable tool in the study of neurodegenerative diseases and related inflammatory mechanisms. It offers researchers a practical means to investigate the role of NLRP3 in various neurological disorders. -
NLRP3 Inhibitor
JNJ-79883960 is a potent NLRP3 inhibitor, designed to modulate the NLRP3 inflammasome's activity. This compound has demonstrated efficacy in reducing inflammation, making it a valuable tool for investigating inflammatory pathways and associated diseases. Its application includes research into conditions such as autoimmune disorders and chronic inflammatory diseases, providing insights into potential therapeutic interventions. -
NLRP3 Inhibitor
NLRP3-IN-65 is a selective inhibitor of the NLRP3 inflammasome, a key component of the innate immune response. This compound exerts significant biological activity by inhibiting the activation of NLRP3, thereby modulating inflammatory responses. It is valuable for research applications related to autoinflammatory diseases, chronic inflammation, and potential therapeutic strategies aimed at controlling NLRP3-mediated pathways. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-4 is a potent inhibitor of the NOD-like receptor (NLR) NLRP3 inflammasome, exhibiting oral bioavailability. This compound is characterized by its ability to mitigate inflammatory processes, making it particularly relevant for research in inflammatory diseases such as colitis. It is a valuable tool for investigating the role of NLRP3 in immune responses and inflammation modulation. -
NLRP3 Inhibitor
NLRP3-IN-64 is a selective inhibitor of the NLRP3 inflammasome, exhibiting an EC50 of 5 nM for the inhibition of NLRP3 activation. This compound is useful for investigating the role of NLRP3 in inflammatory diseases and provides a valuable tool for research in immune response modulation. Its application extends to studying the mechanisms underlying autoinflammatory conditions and potential therapeutic interventions. -
NQO2 Activator
NQO2 activator-1 is a selective activator of NAD(P)H:quinone oxidoreductase 2 (NQO2) that enhances enzymatic activity by 20.89% at a concentration of 10 μM. This compound exhibits a strong inhibitory effect on NLRP3 inflammasome activation, making it a valuable tool for studying inflammation and immunological responses. Research applications include investigations into conditions such as rheumatoid arthritis and other inflammatory disorders. -
NLRP3 Inhibitor
Sebrinoflast is a potent NLRP3 inhibitor, exhibiting an IC50 of ≤1 μM for human NLRP3. This compound is valuable in the study of inflammatory conditions and cardiovascular diseases such as non-alcoholic steatohepatitis (NASH) and atherosclerosis. Additionally, it serves as an important tool in neurological disease research, particularly for Alzheimer's disease. -
NLRX1 Modulator
(6Z,9Z,12Z,15Z,18Z,21Z)-Tetracosahexaenoyl-CoA is a modulator of NLRX1, a member of the NLR family involved in the regulation of immune responses. This compound plays a significant role in the study of immune and metabolic disorders, offering insights into potential therapeutic mechanisms. Its unique structure facilitates research into cellular processes related to inflammation and metabolism. -
NLRP3 Inflammasome Inhibitor
NT-0527 is a selective inhibitor of the NLRP3 inflammasome, demonstrating oral bioavailability and effective permeability across the blood-brain barrier. This compound specifically prevents NLRP3 inflammasome formation, leading to decreased maturation and secretion of interleukin-1 beta (IL-1β). NT-0527 exhibits notable anti-inflammatory effects in models of acute inflammation, including the LPS/ATP-induced peritonitis model. It is a valuable tool for research into neuroinflammatory conditions, such as Parkinson's disease and Alzheimer's disease, as well as peripheral inflammatory disorders like type II diabetes and atherosclerosis involving the NLRP3 pathway. -
NOD-like Receptor (NLR) Inhibitor
GSK223 is a quinazolinone compound that acts as a selective inhibitor of the NOD1 pathway. It demonstrates potential anti-inflammatory activity by selectively inhibiting IL-8 release in response to iE-DAP stimulation, while leaving IL-8 secretion unaffected from TNF receptor, TLR2, or NOD2 agonists. Additionally, GSK223 does not directly inhibit RIP2 kinase activity, making it a valuable tool for studying NOD-like receptor signaling and its implications in inflammatory responses. -
NOD-like Receptor (NLR) Inhibitor
NLRP3-IN-53 is a potent inhibitor of the NOD-like receptor NLRP3, exhibiting an IC50 of 3.4 nM. This compound is utilized in research to investigate the roles of the NLRP3 inflammasome in various inflammatory diseases and immune responses. Its selective inhibition helps elucidate the mechanistic pathways involved in NLRP3-related signaling, making it a valuable tool for studying therapeutic targets in the context of autoimmunity and metabolic disorders. -
NLRP3 Inhibitor
NLRP3-IN-58 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 3.85 μM. At a concentration of 10 μM, it effectively reduces IL-1β release by 33%. This compound is valuable for research applications focused on inflammatory pathways and the modulation of innate immune responses. -
NLRP3 Inhibitor
NLRP3-IN-56 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing IL-1β secretion in THP-1 cells with an IC50 of 9.7 nM. This compound serves as a valuable tool for investigating NLRP3-mediated inflammatory responses and associated pathologies. Its ability to modulate IL-1β levels makes it suitable for research into diseases characterized by NLRP3 activation. -
NLRP3 Inhibitor
NLRP3-IN-28 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an EC50 of 0.07 μM in the inhibition of Nigericin-induced pyroptosis. This compound effectively reduces inflammatory responses in vivo, making it a valuable tool for investigating NLRP3-related diseases and inflammatory pathways. Its application in research provides insights into therapeutic strategies targeting inflammasome activation and related inflammatory conditions. -
Inflammasome Inhibitor
3-Et-3TC is a potent inhibitor of the NLRP3 inflammasome, demonstrating its capacity to modulate inflammasome activation. This compound is valuable for investigating the underlying mechanisms of retinal degenerative diseases and other inflammatory conditions. Its structural modification from Lamivudine enhances its efficacy in biochemical research applications targeting inflammasome pathways. -
PD-L1 Inhibitor
INCB086550 is a potent oral small-molecule inhibitor of PD-L1, exhibiting IC50 values of 3.1, 4.9, and 1.9 nM for human, cynomolgus, and rat PD-L1, respectively. This compound promotes the dimerization of cell-surface PD-L1 and facilitates its entry into Golgi vesicles, leading to nuclear trafficking. INCB086550 is primarily used in cancer research, particularly in studies focusing on immune checkpoint regulation and tumor microenvironment modulation. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-9 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 3.8 nM. This compound enhances the antitumor activity of immune cells against tumor cells. Additionally, PD-1/PD-L1-IN-9 demonstrates significant in vivo antitumor efficacy in the CT26 mouse model, making it a valuable tool for cancer immunotherapy research. -
PD-L1 Inhibitor
BMS-986189 is a macrocyclic peptide that functions as a highly potent PD-L1 inhibitor, demonstrating an IC50 of 1.03 nM in disrupting the PD-1/PD-L1 interaction. This compound is suitable for cancer research applications, particularly in studies involving human lung carcinoma cells such as L2987, making it valuable for exploring immune checkpoint mechanisms and developing novel therapeutic strategies. -
PD-1/PD-L1 Inhibitor
BMS-8 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.2 μM. It directly binds to PD-L1, promoting the formation of PD-L1 homodimers, thereby obstructing the engagement with PD-1. This compound is primarily utilized in cancer immunotherapy research, particularly in studies focused on the modulation of immune checkpoint pathways. -
PD-L1 Binding Peptide
WL12 is a PD-L1 binding peptide that specifically targets the programmed death ligand 1. This peptide can be radiolabeled with various radionuclides to create radiotracers, facilitating the assessment of PD-L1 expression in tumors. It is a valuable tool for cancer research, particularly in studies focused on immune checkpoint blockade and tumor immunology. -
PD-1/PD-L1 PPI Inhibitor
Evixapodlin is a potent inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 of 0.213 nM. This compound demonstrates significant anticancer and antiviral activities, making it a valuable tool for research in immunotherapy and viral pathogenesis. Evixapodlin is particularly useful for studying the modulation of immune responses in tumor environments and understanding the interplay between immune checkpoints and viral infections. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-14 is a bifunctional inhibitor specifically targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 27.8 nM. This compound effectively disrupts PD-1/PD-L1 binding while promoting the dimerization, internalization, and degradation of PD-L1. Its unique mechanism of action supports research in immunotherapy and cancer treatment, making it a valuable tool for studies involving immune modulation and T-cell activation. -
PD-L1 Inhibitor
PD-L1-IN-3 is a PD-L1 inhibitor that effectively targets the PD-1/PD-L1 interaction. With an IC50 value of 4.97 nM for inhibiting PD-L1 and an EC50 value of 2.70 μM for Jurkat T cell activation, this compound disrupts PD-1 signaling by binding to the PD-L1 dimer. PD-L1-IN-3 is particularly valuable for research applications in lung cancer and melanoma, facilitating the study of immune checkpoint mechanisms in these diseases. -
PD-1/PD-L1 Inhibitor
MAX-10181 is a selective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 0.018 μM. This compound is instrumental in cancer research, facilitating the exploration of immune checkpoint blockade mechanisms and potential therapeutic applications in oncology and related diseases. Researchers can utilize MAX-10181 to study the modulation of immune responses in various tumor models. -
PD-1/PD-L1 Inhibitor
ARB-272572 is a potent small molecule inhibitor targeting the PD-L1 pathway, exhibiting an IC50 value of 400 pM. This compound enhances antitumor immunity and shows promise in the treatment of chronic viral infections. ARB-272572 is valuable for research applications focused on cancer immunotherapy and viral infection studies. -
PD-L1/TGF β Fusion Protein
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein that targets programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). This compound is designed to enhance anti-tumor immunity by concurrently inhibiting immune checkpoint pathways and modulating the tumor microenvironment. SHR-1701 is valuable for research applications focused on cancer immunotherapy and the modulation of TGF-β signaling in various malignancies. -
PD-L1 Antagonist
CVARARTR is a potent antagonist of programmed cell death ligand-1 (PD-L1) with a dissociation constant (KD) of 281 nM. It promotes the internalization of PD-L1, leading to a decrease in its surface expression. This mechanism effectively restores cytokine secretion and enhances T cell proliferation in CT26 cells. Additionally, CVRARTR demonstrates antitumor efficacy in the CT26 homograft mouse model, making it a valuable tool for research in melanoma and immunotherapy studies. -
PD-1/PD-L1 Inhibitor
N-deacetylated BMS-202 is a potent inhibitor of the PD-1/PD-L1 interaction. This compound plays a significant role in cancer immunotherapy by blocking the immune checkpoint pathway, thereby enhancing T-cell responses against tumor cells. Its application in research encompasses the investigation of tumor microenvironments and the evaluation of immune evasion mechanisms in various cancer types. -
PD-L1/PD-1 Inhibitor
BMS-1001 hydrochloride is an orally active inhibitor of the PD-L1/PD-1 immune checkpoint pathway. It demonstrates low cytotoxicity across various cell lines, making it suitable for research applications. The compound has an IC50 value of 2.25 nM in homogeneous time-resolved fluorescence (HTRF) binding assays, indicating potent inhibition of PD-1 interactions. BMS-1001 is useful for studies focused on cancer immunotherapy and the modulation of immune responses. -
Anti-PD-1 Antibody/IL-21 Mutein
Latikafusp is a bifunctional fusion protein that functions as an anti-PD-1 antibody paired with an IL-21 mutein. This compound is designed to stimulate the IL-21 pathway specifically in PD-1+ cells, enhancing the priming and persistence of cytotoxic and memory T cells to promote anti-tumor immunity. Latikafusp is particularly relevant in research focused on solid tumors and has the potential to elicit immunogenicity-mediated responses. -
PD-1/PD-L1 Inhibitor
ASC-69 is a potent inhibitor of the PD-1/PD-L1 pathway, which plays a critical role in immune evasion by tumors. This small-molecule compound demonstrates strong biological activity in inhibiting the interaction between PD-1 and PD-L1, thereby enhancing T-cell responses against cancer cells. ASC-69 is relevant for research applications focused on cancer immunotherapy and the modulation of immune checkpoint mechanisms. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-33 is a potent inhibitor of the PD-1/PD-L1 interaction, demonstrating an IC50 of 6.3 nM. This compound enhances T-cell proliferation, activation, and infiltration into tumor microenvironments, thereby exerting immunomodulatory and anticancer effects. PD-1/PD-L1-IN-33 is applicable in research focused on cancer immunotherapy and the modulation of immune responses. -
PD-L1 Inhibitor
BMS-986238 is an orally active macrocyclic peptide that functions as a PD-L1 inhibitor. This compound exhibits significant anti-tumor activity by blocking the PD-1/PD-L1 interaction, enhancing immune responses against cancer cells. BMS-986238 is utilized in research applications focusing on solid tumors and lymphomas, providing insights into immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-23 is a potent, orally active inhibitor of the PD-1/PD-L1 interaction. As an ester proagent of L7, a benzo[c][1,2,5]oxadiazole derivative, it has been evaluated for its ability to inhibit PD-L1. This compound demonstrates significant antitumor effects in various tumor models, including syngeneic and PD-L1 humanized mice, making it a valuable tool for cancer research and the development of immune checkpoint therapies. -
PD-L1 Inhibitor
PD-L1-IN-2 is an inhibitor of the programmed death-ligand 1 (PD-L1) pathway, functioning as a potential immunotherapeutic agent against tumors. This Naamidine J derivative demonstrates significant antitumor activity by downregulating PD-L1 expression, thereby enhancing T-cell infiltration and activity within tumors. PD-L1-IN-2 is applicable in preclinical research focused on colorectal cancer and other malignancies where PD-L1 plays a critical role in immune evasion. -
PD-1/PD-L1 Interaction Inhibitor
BMSpep-57 is a competitive macrocyclic peptide inhibitor targeting the PD-1/PD-L1 interaction, exhibiting an IC50 of 7.68 nM. It demonstrates strong binding affinity to PD-L1, with Kd values of 19 nM in Microscale Thermophoresis (MST) and 19.88 nM in Surface Plasmon Resonance (SPR) assays. By disrupting this interaction, BMSpep-57 enhances T cell function, leading to increased IL-2 production in peripheral blood mononuclear cells (PBMCs). This compound is valuable for research applications related to immunotherapy and T cell activation. -
PD-1/PD-L1 Inhibitor
Kaempferol-7-O-rhamnoside is a potent inhibitor of the PD-1/PD-L1 pathway and an agonist of the farnesoid X receptor (FXR). It exhibits cardioprotective properties by targeting the AMPKα1 signaling pathway, significantly enhancing mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Additionally, Kaempferol-7-O-rhamnoside effectively reverses acetaminophen-induced reductions in glutathione levels and mitigates reactive oxygen species production in L02 cells. This compound demonstrates potential applications in research related to heart failure and oxidative stress. -
PD-1 Inhibitor
PD-1-IN-24 is a potent inhibitor of the programmed cell death protein 1 (PD-1) pathway, demonstrating robust oral bioavailability. This compound effectively modulates immune responses by blocking PD-1 interaction with its ligands, which is crucial for enhancing anti-tumor immunity. PD-1-IN-24 is utilized in research to investigate immune regulation and develop cancer immunotherapies. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-29 is a potent inhibitor of the PD-1/PD-L1 pathway, exhibiting an IC50 value of 6.1 nM. This compound effectively binds to PD-L1 to disrupt PD-1/PD-L1 interactions, facilitating PD-L1 dimerization and subsequent internalization, while enhancing its localization to the endoplasmic reticulum. PD-1/PD-L1-IN-29 demonstrates significant anticancer activity, making it a valuable tool for research in immuno-oncology and therapeutic applications targeting immune checkpoint pathways. -
PD-1/PD-L1 Inhibitor
BMS-37 is a potent PD-1/PD-L1 immune checkpoint inhibitor, demonstrating an IC50 ranging from 18 to 200 nM against the PD-L1/PD-1 complex. This compound exhibits significant toxicity toward modified Jurkat T cells, with an EC50 between 3 and 6 µM. BMS-37 is valuable for investigating PD-L1-mediated T-cell exhaustion and serves as a PD-L1 ligand in the synthesis of PROTAC molecules for targeted protein degradation studies. -
PD-1/PD-L1 Interaction Inhibitor
BMS-200 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 80 nM. This compound effectively disrupts the binding of PD-L1 to PD-1, which is critical in regulating immune responses. BMS-200 is valuable for research in cancer immunotherapy, particularly in elucidating mechanisms of immune checkpoint modulation. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-NP19 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 12.5 nM. This compound is designed to enhance immune responses within the tumor microenvironment, potentially leading to significant antitumor activity. It is a valuable tool for researchers investigating immunotherapy and the modulation of immune checkpoints in cancer therapy. -
PD-1 Agonist
H-20 is a potent PD-1 agonist that modulates immune responses by enhancing programmed cell death protein 1 signaling. This compound demonstrates significant biological activity in research related to chronic pain and immune regulation. Its applications extend to investigating the therapeutic potential of PD-1 activation in managing pain conditions and understanding the underlying mechanisms involved in chronic inflammatory responses. -
Inhibitor of PD-1/PD-L1 Protein-Protein Interaction
LH1307 is a C2-symmetric inhibitor of the PD-1/PD-L1 protein-protein interaction, exhibiting an IC50 value of 3.0 μM. This compound serves as a valuable tool for cancer research, enabling the exploration of immunotherapeutic strategies targeting the PD-1/PD-L1 axis. Its application can facilitate studies on immune evasion mechanisms in tumors and the development of novel cancer therapies. -
PD-1/PD-L1 Interaction Inhibitor
PD-1/PD-L1-IN-13 is a potent inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 value of 10.2 nM. This compound effectively promotes CD8+ T cell activation, enhancing anti-tumor immunity. Its application in preclinical models, such as the Hepa1-6 syngeneic mouse model, demonstrates its potential to delay tumor growth, making it valuable for research in immunotherapy and cancer biology. -
hPD-1/hPD-L1 Interaction Inhibitor
Human PD-L1 inhibitor V is a peptide that specifically targets the interaction between human PD-1 and PD-L1, exhibiting a binding affinity characterized by a Kd value of 3.32 μM. This inhibitor is valuable for research applications focused on immune checkpoint modulation and cancer immunotherapy, as it effectively disrupts the PD-1/PD-L1 signaling pathway, which is critical in the regulation of immune responses. -
PD-L1 Inhibitor
Human PD-L1 Inhibitor IV is a competitive inhibitor of the human PD-1 protein, exhibiting a Kd value of 1.38 μM. This polypeptide effectively disrupts the interaction between human PD-1 and PD-L1, facilitating research into immune checkpoint pathways. It is applicable for studies focused on cancer immunotherapy and the modulation of immune responses. -
PD-1/PD-L1 Inhibitor
IMMH-010 maleate is a prodrug that functions as a PD-L1 inhibitor, demonstrating significant potential for antitumor activity in neurological disorders and advanced malignant solid tumors. Upon oral administration, IMMH-010 maleate is swiftly converted to its active form, YPD-29B. This compound is designed to facilitate research in the area of PD-L1 inhibition and its therapeutic implications. -
PD-1 Inhibitor
PD1-PDL1-IN 1 is a potent inhibitor of programmed cell death 1 (PD-1), a critical checkpoint in immune regulation. This compound serves as an immune modulator, facilitating enhanced T-cell activation and proliferation. PD1-PDL1-IN 1 is valuable for research applications focused on cancer immunotherapy and elucidating immune response mechanisms.
